Filtrer vos résultats
- 3
- 1
- 4
- 4
- 1
- 2
- 1
- 4
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2021, 204 (1), pp.64-73. ⟨10.1164/rccm.202011-4153OC⟩
Article dans une revue
hal-03704955v1
|
|||
Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutationsEuropean Respiratory Journal, 2019, 54 (63), ⟨10.1183/13993003.congress-2019.OA2140⟩
Article dans une revue
hal-03591325v1
|
|||
|
Safety and efficacy of pirfenidone and nintedanib in patients with Idiopathic Pulmonary Fibrosis and carrying a telomere related gene mutationEuropean Respiratory Journal, 2021, 57 (2), pp.2003198. ⟨10.1183/13993003.03198-2020⟩
Article dans une revue
hal-03094894v1
|
||
|
French recommendations for the diagnosis and management of lymphangioleiomyomatosisRespiratory Medicine and Research, 2023, 83, pp.101010. ⟨10.1016/j.resmer.2023.101010⟩
Article dans une revue
hal-04083634v1
|